Full Press Release Details
GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024. Details of the event and replay are as follows:
| Conference call details: | |
| Date: | November 12, 2024 |
| Time: | 8:30 a.m. U.S. ET |
| URL to register phone: | https://emportal.ink/3Y6irHG |
| Dial-in number: | (800) 836-8184 (Domestic) or |
| (+1) (646) 357-8785 (International) | |
| Webcast: | ir.novavax.com/events |
Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
| Replay details: | |
| Date: | Available starting at 11:30 a.m. ET, November 12, 2024, until 11:59 p.m. U.S. ET, November 19, 2024 |
| Dial-in number: | (888) 660-6345 (Domestic) or |
| (+1) (646) 517-4150 (International) | |
| Passcode: | 62491 # |
| Webcast: | ir.novavax.com/events , until December 12, 2024 |
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
SOURCE Novavax, Inc.
21 %
more press release views with